迪安诊断(300244) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 3.23 billion, a decrease of 30.48% compared to CNY 4.65 billion in the same period last year[9]. - The net profit attributable to shareholders for Q1 2023 was CNY 160 million, down 78.74% from CNY 753.71 million year-on-year[9]. - The net profit excluding non-recurring items for Q1 2023 was CNY 139 million, a decline of 81.47% compared to CNY 747.65 million in the previous year[9]. - The total comprehensive income attributable to the parent company was ¥160,273,989.61, down from ¥753,710,562.37, showing a decline of approximately 78.8%[33]. - Basic earnings per share dropped to ¥0.2557 from ¥1.2148, reflecting a decrease of about 78.9%[33]. Cash Flow - The company's cash flow from operating activities improved to -CNY 228.73 million, a 76.50% increase from -CNY 973.14 million in the same period last year[7]. - The cash flow from investment activities improved to -CNY 75.06 million, a 61.65% increase from -CNY 195.74 million year-on-year[7]. - The net cash flow from investing activities was -75,059,602.72 CNY, an improvement from -195,744,317.28 CNY in the previous year[36]. - The total cash inflow from financing activities was 189,752,063.35 CNY, down from 1,719,594,332.00 CNY in the same period last year[36]. - The company reported a net cash flow from financing activities of -301,079,035.95 CNY, compared to a positive flow of 473,419,812.78 CNY last year[36]. Assets and Liabilities - The total assets as of March 31, 2023, were CNY 21.06 billion, reflecting a slight increase of 0.50% from the end of the previous year[15]. - Current liabilities decreased to ¥7,323,507,701.78 from ¥7,747,956,631.67, representing a reduction of about 5.5%[28]. - The total liabilities increased to ¥7,323,507,701.78, compared to the previous period's liabilities of ¥7,747,956,631.67, indicating a decrease of about 5.5%[28]. - The company's total equity increased to ¥10,187,640,437.33 from ¥9,501,998,668.78, representing an increase of approximately 7.2%[51]. - The company's long-term borrowings decreased to ¥2,823,290,000.00 from ¥2,968,290,000.00, a decline of about 4.9%[51]. Investments and R&D - The long-term equity investment decreased by 47.42% to CNY 570 million due to the acquisition of a joint venture[7]. - The company invested 100 million CNY in R&D during the reporting period[42]. - The company established a new investment partnership in March 2023 with a total fund registration completion[47]. Revenue Breakdown - Revenue from diagnostic services reached 1.222 billion CNY, a year-on-year increase of 26.21% excluding COVID-related business[42]. - Revenue from self-developed products grew to 124 million CNY, marking a 51.22% increase year-on-year excluding COVID-related business[42]. - The total revenue from channel products was 1.998 billion CNY, reflecting a 9.39% year-on-year growth[42]. Other Income and Expenses - The company reported a significant increase in other income, which rose by 362.89% to CNY 21.32 million, primarily due to increased government subsidies[7]. - The sales expenses for Q1 2023 were CNY 262.26 million, down 32.75% from CNY 390 million in the previous year, attributed to the decline in revenue[7]. - The company recorded a government subsidy of 21,554,557.43 CNY during the reporting period[40]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,155[43]. - The company completed a share buyback of 1,918,600 shares, accounting for 0.31% of the total share capital, with a total transaction amount of CNY 49.99 million[25].